FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282912962> ?p ?o ?g. }

• W4282912962 endingPage "CT252" @default.
• W4282912962 startingPage "CT252" @default.
• W4282912962 abstract "Abstract Background: Toll-like receptors (TLRs) play a key role in innate immune cell recognition of foreign pathogens, stimulating innate and adaptive immune responses. TLR agonists amplify tumor antigen-specific immune responses in the context of anti-PD-1 therapy. TransCon TLR7/8 Agonist is designed as a long-acting prodrug to provide localized delivery of resiquimod, a potent TLR7/8 agonist. TransCon TLR7/8 Agonist has the potential to improve on challenges of pattern recognition receptor agonist treatments by providing prolonged high local concentrations of resiquimod and promoting potent anti-tumoral responses while reducing systemic drug exposure and related adverse events. TransCon TLR7/8 Agonist comprises 3 main components: resiquimod, a polymeric hydrogel microparticle carrier, and a linker bound permanently to the hydrogel microparticle carrier on one end and transiently to resiquimod on the other. TLR-mediated T cell activation induces PD-1 expression on T cells, providing a clear rationale to study TransCon TLR7/8 Agonist alone and in combination with pembrolizumab (pembro). Intratumoral TransCon TLR7/8 Agonist is expected to stimulate innate and adaptive immune response in the tumor microenvironment and further enhance the activity of checkpoint inhibitors like pembro. Methods: transcendIT-101 is a multicenter, first-in-human, Phase 1/2 study in 3 parts in adult patients with locally advanced, unresectable, recurrent, or metastatic solid tumors. All patients must have at least 2 measurable lesions by RECIST 1.1 that are predesignated as target-injected and target non-injected lesions, respectively. The primary objectives are to evaluate the safety, tolerability, define the maximum tolerated dose and recommended Phase 2 dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembro. Parts 1 and 2 Dose Escalation (Phase 1) use a standard 3+3 design with increasing doses of TransCon TLR7/8 Agonist alone (Part 1) or with 200 mg intravenous pembro in solid tumors where pembro monotherapy may have clinical activity (Part 2). Each part will enroll ≈20 patients. Part 3 Combination Dose Expansion (Phase 2) will evaluate preliminary clinical efficacy of TransCon TLR7/8 Agonist at the RP2D determined in Part 2 combined with pembro. Currently planned expansion cohorts are 1) head and neck squamous cell carcinoma, 2) other HPV-associated tumors (anal, vulvar, cervical, penile, vaginal). Each cohort will be analyzed using a Simon 2-stage design and will enroll ≈50 patients. Secondary objectives are TransCon TLR7/8 Agonist pharmacokinetics and its antitumor activity using ORR, duration of response, time to response by RECIST 1.1 and itRECIST; progression-free survival; overall survival. Recruitment started March 2021 and is ongoing (NCT04799054). Citation Format: Diwakar Davar, Stina M. Singel, Gil Nyamuswa, Tuan-Anh Tran, Yang Wu, Jaspreet Grewal, Morteza Aghmesheh, Alexander Spira, Vinod Ganju, Jamie Rand, Sophia Frentzas, David Bajor, Nashat Gabrail. transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT252." @default.
• W4282912962 created "2022-06-16" @default.
• W4282912962 creator A5016927526 @default.
• W4282912962 creator A5018587056 @default.
• W4282912962 creator A5030169825 @default.
• W4282912962 creator A5034486818 @default.
• W4282912962 creator A5040489877 @default.
• W4282912962 creator A5044613951 @default.
• W4282912962 creator A5049181098 @default.
• W4282912962 creator A5051445471 @default.
• W4282912962 creator A5052270503 @default.
• W4282912962 creator A5075528541 @default.
• W4282912962 creator A5076779423 @default.
• W4282912962 creator A5082283453 @default.
• W4282912962 creator A5086027996 @default.
• W4282912962 date "2022-06-15" @default.
• W4282912962 modified "2023-10-07" @default.
• W4282912962 title "Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors" @default.
• W4282912962 doi "https://doi.org/10.1158/1538-7445.am2022-ct252" @default.
• W4282912962 hasPublicationYear "2022" @default.
• W4282912962 type Work @default.
• W4282912962 citedByCount "0" @default.
• W4282912962 crossrefType "journal-article" @default.
• W4282912962 hasAuthorship W4282912962A5016927526 @default.
• W4282912962 hasAuthorship W4282912962A5018587056 @default.
• W4282912962 hasAuthorship W4282912962A5030169825 @default.
• W4282912962 hasAuthorship W4282912962A5034486818 @default.
• W4282912962 hasAuthorship W4282912962A5040489877 @default.
• W4282912962 hasAuthorship W4282912962A5044613951 @default.
• W4282912962 hasAuthorship W4282912962A5049181098 @default.
• W4282912962 hasAuthorship W4282912962A5051445471 @default.
• W4282912962 hasAuthorship W4282912962A5052270503 @default.
• W4282912962 hasAuthorship W4282912962A5075528541 @default.
• W4282912962 hasAuthorship W4282912962A5076779423 @default.
• W4282912962 hasAuthorship W4282912962A5082283453 @default.
• W4282912962 hasAuthorship W4282912962A5086027996 @default.
• W4282912962 hasConcept C126322002 @default.
• W4282912962 hasConcept C136449434 @default.
• W4282912962 hasConcept C170493617 @default.
• W4282912962 hasConcept C197934379 @default.
• W4282912962 hasConcept C203014093 @default.
• W4282912962 hasConcept C2776090121 @default.
• W4282912962 hasConcept C2776709828 @default.
• W4282912962 hasConcept C2777701055 @default.
• W4282912962 hasConcept C2778375690 @default.
• W4282912962 hasConcept C2778938600 @default.
• W4282912962 hasConcept C2779836521 @default.
• W4282912962 hasConcept C2780057760 @default.
• W4282912962 hasConcept C502942594 @default.
• W4282912962 hasConcept C71924100 @default.
• W4282912962 hasConcept C8891405 @default.
• W4282912962 hasConcept C98274493 @default.
• W4282912962 hasConceptScore W4282912962C126322002 @default.
• W4282912962 hasConceptScore W4282912962C136449434 @default.
• W4282912962 hasConceptScore W4282912962C170493617 @default.
• W4282912962 hasConceptScore W4282912962C197934379 @default.
• W4282912962 hasConceptScore W4282912962C203014093 @default.
• W4282912962 hasConceptScore W4282912962C2776090121 @default.
• W4282912962 hasConceptScore W4282912962C2776709828 @default.
• W4282912962 hasConceptScore W4282912962C2777701055 @default.
• W4282912962 hasConceptScore W4282912962C2778375690 @default.
• W4282912962 hasConceptScore W4282912962C2778938600 @default.
• W4282912962 hasConceptScore W4282912962C2779836521 @default.
• W4282912962 hasConceptScore W4282912962C2780057760 @default.
• W4282912962 hasConceptScore W4282912962C502942594 @default.
• W4282912962 hasConceptScore W4282912962C71924100 @default.
• W4282912962 hasConceptScore W4282912962C8891405 @default.
• W4282912962 hasConceptScore W4282912962C98274493 @default.
• W4282912962 hasIssue "12_Supplement" @default.
• W4282912962 hasLocation W42829129621 @default.
• W4282912962 hasOpenAccess W4282912962 @default.
• W4282912962 hasPrimaryLocation W42829129621 @default.
• W4282912962 hasRelatedWork W2585407512 @default.
• W4282912962 hasRelatedWork W2735721991 @default.
• W4282912962 hasRelatedWork W2801068490 @default.
• W4282912962 hasRelatedWork W2891524425 @default.
• W4282912962 hasRelatedWork W3037068108 @default.
• W4282912962 hasRelatedWork W3041652591 @default.
• W4282912962 hasRelatedWork W3191427281 @default.
• W4282912962 hasRelatedWork W4200023723 @default.
• W4282912962 hasRelatedWork W4311628015 @default.
• W4282912962 hasRelatedWork W4323543912 @default.
• W4282912962 hasVolume "82" @default.
• W4282912962 isParatext "false" @default.
• W4282912962 isRetracted "false" @default.
• W4282912962 workType "article" @default.